ANVS
Price
$1.74
Change
-$0.12 (-6.45%)
Updated
Jul 13, 04:59 PM (EDT)
Capitalization
74.87M
36 days until earnings call
Intraday BUY SELL Signals
CCXI
Price
$14.34
Change
-$1.21 (-7.78%)
Updated
Jul 13 closing price
Capitalization
799.29M
Intraday BUY SELL Signals
Interact to see
Advertisement

ANVS vs CCXI

ANVS vs CCXI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANVS vs. CCXI commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVS is a Buy and CCXI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (ANVS: $1.86 vs. CCXI: $15.55)
Brand notoriety: ANVS and CCXI are both not notable
ANVS represents the Biotechnology, while CCXI is part of the Financial Conglomerates industry
Current volume relative to the 65-day Moving Average: ANVS: 104% vs. CCXI: 143%
Market capitalization -- ANVS: $74.87M vs. CCXI: $799.29M
ANVS [@Biotechnology] is valued at $74.87M. CCXI’s [@Financial Conglomerates] market capitalization is $799.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The market cap for tickers in the [@Financial Conglomerates] industry ranges from $590.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B. The average market capitalization across the [@Financial Conglomerates] industry is $267.18M.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANVS’s FA Score shows that 0 FA rating(s) are green whileCCXI’s FA Score has 1 green FA rating(s).

  • ANVS’s FA Score: 0 green, 5 red.
  • CCXI’s FA Score: 1 green, 4 red.
According to our system of comparison, CCXI is a better buy in the long-term than ANVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANVS’s TA Score shows that 3 TA indicator(s) are bullish while CCXI’s TA Score has 3 bullish TA indicator(s).

  • ANVS’s TA Score: 3 bullish, 5 bearish.
  • CCXI’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, CCXI is a better buy in the short-term than ANVS.

Price Growth

ANVS (@Biotechnology) experienced а -3.63% price change this week, while CCXI (@Financial Conglomerates) price change was -18.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +7.30%, and the average quarterly price growth was +1806.57%.

The average weekly price growth across all stocks in the @Financial Conglomerates industry was -0.18%. For the same industry, the average monthly price growth was -0.07%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

ANVS is expected to report earnings on Aug 18, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Financial Conglomerates (-0.18% weekly)

Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CCXI($799M) has a higher market cap than ANVS($74.9M). ANVS has more cash in the bank: 14.2M vs. CCXI (410K).
ANVSCCXIANVS / CCXI
Capitalization74.9M799M9%
EBITDA-41.42MN/A-
Gain YTD-49.133N/A-
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash14.2M410K3,463%
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ANVS vs CCXI: Fundamental Ratings
ANVS
CCXI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6043
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANVS's Valuation (68) in the null industry is in the same range as CCXI (100) in the Biotechnology industry. This means that ANVS’s stock grew similarly to CCXI’s over the last 12 months.

CCXI's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as ANVS (100) in the null industry. This means that CCXI’s stock grew similarly to ANVS’s over the last 12 months.

CCXI's SMR Rating (99) in the Biotechnology industry is in the same range as ANVS (100) in the null industry. This means that CCXI’s stock grew similarly to ANVS’s over the last 12 months.

CCXI's Price Growth Rating (43) in the Biotechnology industry is in the same range as ANVS (60) in the null industry. This means that CCXI’s stock grew similarly to ANVS’s over the last 12 months.

CCXI's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for ANVS (100) in the null industry. This means that CCXI’s stock grew significantly faster than ANVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANVSCCXI
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
58%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 5 days ago
67%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
46%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
63%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
ANVS
Daily Signal:
Gain/Loss:
CCXI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCGNX28.40N/A
N/A
William Blair Large Cap Growth N
LAFPX22.55N/A
N/A
Lord Abbett Affiliated P
IASCX13.94N/A
N/A
Voya Small Company Port A
MRAGX30.88N/A
N/A
Meridian Growth A
CIEQX15.70N/A
N/A
Segall Bryant & Hamll Intl Eq Inst

ANVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANVS
1D Price
Change %
ANVS100%
-5.38%
ADXN - ANVS
43%
Loosely correlated
-0.70%
MDGL - ANVS
36%
Loosely correlated
-1.06%
JAZZ - ANVS
35%
Loosely correlated
-2.81%
AMLX - ANVS
34%
Loosely correlated
-2.03%
CCXI - ANVS
34%
Loosely correlated
-7.78%
More

CCXI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CCXI has been loosely correlated with SPRO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CCXI jumps, then SPRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CCXI
1D Price
Change %
CCXI100%
-7.78%
SPRO - CCXI
48%
Loosely correlated
+3.81%
ABOS - CCXI
48%
Loosely correlated
+0.38%
ANVS - CCXI
34%
Loosely correlated
-5.38%
IPHA - CCXI
34%
Loosely correlated
+0.28%
IDYA - CCXI
34%
Loosely correlated
-2.27%
More